PFBT
SAGE

Parkside Financial Bank & Trust’s Sage Therapeutics SAGE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60
Closed -$547 – 2797
2025
Q2 		$547 Buy
+60
New +$441 ﹤0.01% 2500
2022
Q1 		– Sell
-4
Closed – – 1921
2021
Q4 		$0 Buy
+4
New +$167 ﹤0.01% 1904

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Parkside Financial Bank & Trust's SAGE Position: Q3 2025 in Review

Parkside Financial Bank & Trust sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 60 shares — an estimated $547 sold.

Parkside Financial Bank & Trust first reported a position in SAGE in Q4 2021 and held it in 2 quarters. The position peaked at $547 in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Parkside Financial Bank & Trust reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 60 Sage Therapeutics shares in Q3 2025, an estimated $547.
  • Parkside Financial Bank & Trust first reported a position in Sage Therapeutics in Q4 2021 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Sage Therapeutics position peaked at $547 in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q3 2025, filed 30 Oct 2025.